|
|
|
|
|
|
|
|
|
|
"The drugmaker then said that its investigational compound olaparib would not progress into Phase III development for the maintenance treatment of serous ovarian cancer. Additionally, attempts to identify a suitable tablet dose for use in Phase III studies were not successful."
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.